Autopsy report · NCT02961816

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.

“Lack of funding”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 2
Sponsor: M.D. Anderson Cancer Center
Sponsor type: University, hospital or other
Conditions: Lymphoma
Interventions: Palifermin; Panobinostat; Gemcitabine; Busulfan; Melphalan; Rituximab
Participants: 0

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.